Morgan Stanley raised the firm’s price target on Ascendis Pharma (ASND) to $180 from $175 and keeps an Equal Weight rating on the shares after updating the firm’s model for recently reported Q4 results and rolling forward its valuation date.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Yorvipath: Impressive Launch and Strong Growth Potential Drive Buy Rating
- Potential Share Dilution Looms for Ascendis Pharma: What Investors Need to Know
- Ascendis Pharma A/S Earnings Call Highlights Growth and Challenges
- Ascendis Pharma price target raised to $162 from $153 at TD Cowen
- Ascendis Pharma price target lowered to $192 from $203 at BofA